PURNIMA TEEGAVARAPU to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications PURNIMA TEEGAVARAPU has written about TOR Serine-Threonine Kinases.
Connection Strength
0.107
-
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. BJU Int. 2016 08; 118(2):264-71.
Score: 0.107